- Home
- MNY vs FBLG Comparison
MNY vs FBLG Comparison
Compare MNY & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- FBLG
- Stock Information
- Founded
- MNY 2014
- FBLG 2021
- Country
- MNY Singapore
- FBLG United States
- Employees
- MNY N/A
- FBLG N/A
- Industry
- MNY
- FBLG
- Sector
- MNY
- FBLG
- Exchange
- MNY Nasdaq
- FBLG NYSE
- Market Cap
- MNY 40.6M
- FBLG 37.1M
- IPO Year
- MNY N/A
- FBLG 2024
- Fundamental
- Price
- MNY $0.76
- FBLG $0.86
- Analyst Decision
- MNY
- FBLG Strong Buy
- Analyst Count
- MNY 0
- FBLG 4
- Target Price
- MNY N/A
- FBLG $13.00
- AVG Volume (30 Days)
- MNY 39.4K
- FBLG 144.4K
- Earning Date
- MNY 04-28-2025
- FBLG 05-13-2025
- Dividend Yield
- MNY N/A
- FBLG N/A
- EPS Growth
- MNY N/A
- FBLG N/A
- EPS
- MNY N/A
- FBLG N/A
- Revenue
- MNY $90,185,081.00
- FBLG N/A
- Revenue This Year
- MNY $18.50
- FBLG N/A
- Revenue Next Year
- MNY $24.83
- FBLG N/A
- P/E Ratio
- MNY N/A
- FBLG N/A
- Revenue Growth
- MNY 24.60
- FBLG N/A
- 52 Week Low
- MNY $0.65
- FBLG $0.86
- 52 Week High
- MNY $2.75
- FBLG $13.59
- Technical
- Relative Strength Index (RSI)
- MNY 39.55
- FBLG 35.97
- Support Level
- MNY $0.65
- FBLG $0.90
- Resistance Level
- MNY $0.82
- FBLG $1.16
- Average True Range (ATR)
- MNY 0.06
- FBLG 0.08
- MACD
- MNY 0.01
- FBLG 0.01
- Stochastic Oscillator
- MNY 59.75
- FBLG 12.08
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.